Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Single-Arm Study of Nanoliposomal Irinotecan With Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin

NCT03736720 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT03736720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03736720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Single-Arm Study of Nanoliposomal Irinotecan With Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 2
Overall status
Terminated
Start date
June 17, 2019
Completion date
August 26, 2024
Enrollment
11 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced digestive system neuroendocrine carcinoma, locally advanced pancreatic neuroendocrine carcinoma, metastatic digestive system neuroendocrine carcinoma, metastatic pancreatic neuroendocrine carcinoma, refractory digestive system neuroendocrine carcinoma, refractory pancreatic neuroendocrine carcinoma, unresectable digestive system neuroendocrine carcinoma, unresectable pancreatic neuroendocrine carcinoma